A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00267267|
Recruitment Status : Terminated
First Posted : December 20, 2005
Last Update Posted : December 10, 2007
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of combination cholesterol medications to see how the different treatments compare to one another.
|Condition or disease||Intervention/treatment||Phase|
|Hyperlipidemia Dyslipidemia||Drug: torcetrapib/atorvastatin Drug: ezetimibe/simvastatin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||1784 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia.|
|Study Start Date :||January 2006|
|Actual Study Completion Date :||January 2007|
- Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.
- Changes in other lipid parameters and other biomarkers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00267267
Show 123 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|